Post-discharge Malaria Chemoprevention(PMC) Study (PMC)
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial
Sponsor: Kenya Medical Research Institute
Listed as NCT02671175, this PHASE3 trial focuses on Malaria and Severe Anemia and remains completed. Sponsored by Kenya Medical Research Institute, it has been updated 8 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Apr 2019 — Jul 2020 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kenya Medical Research Institute
- Liverpool School of Tropical Medicine
- Makerere University
- The Research Council of Norway
For direct contact, visit the study record on ClinicalTrials.gov .